Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Peru-1 5 (AVANT).

Taff Jones1

  • 1ID Biomedical Corp of Quebec, 7150 Frederick Banting, Montreal H4S 2A1, Quebec, Canada tjones@idbiomedical.com

Current Opinion in Investigational Drugs (London, England : 2000)
|December 17, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of nasal IgA in children vaccinated with live attenuated influenza vaccine.

Vaccine·2012
Same author

Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials.

PloS one·2010
Same author

Vacc-4x, a therapeutic vaccine comprised of four engineered peptides for the potential treatment of HIV infection.

Current opinion in investigational drugs (London, England : 2000)·2010
Same author

GSK's novel split-virus adjuvanted vaccines for the prevention of the H5N1 strain of avian influenza infection.

Current opinion in molecular therapeutics·2009
Same author

IC-51, an injectable vaccine for the prevention of Japanese encephalitis virus infection.

Current opinion in molecular therapeutics·2009
Same author

IMVAMUNE, an attenuated modified vaccinia Ankara virus vaccine for smallpox infection.

Current opinion in molecular therapeutics·2008

Peru-15, a novel single-dose recombinant cholera vaccine, is undergoing clinical trials. Development is progressing towards phase III trials for widespread use and challenge studies in travelers.

Area of Science:

  • Vaccinology
  • Infectious Diseases
  • Clinical Trials

Background:

  • Cholera remains a significant public health concern globally.
  • Development of effective cholera vaccines is crucial for prevention and control.
  • Peru-15 is a novel single-dose recombinant cholera vaccine candidate.

Purpose of the Study:

  • To evaluate the safety and immunogenicity of Peru-15.
  • To assess the efficacy of Peru-15 in preventing cholera.
  • To advance the development of Peru-15 through clinical trials.

Main Methods:

  • Phase II clinical trials were ongoing as of June 2003.
  • Planning for Phase III trials in a developing country was underway.
  • Phase IIb and Phase III challenge studies in travelers were being planned.

Related Experiment Videos

Main Results:

  • Data from ongoing Phase II trials were being analyzed.
  • The vaccine candidate showed promise for further development.
  • Specific efficacy and safety results were pending completion of trials.

Conclusions:

  • Peru-15 represents a promising candidate for cholera prevention.
  • Further clinical trials are necessary to confirm its efficacy and safety.
  • The vaccine has potential for use in both endemic areas and traveler populations.